Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
Clinical trial NCT03534804 · COMPLETED
Trial details
- NCT number
- NCT03534804
- Sponsor
- University of Utah
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-18
- Primary completion
- 2023-08-02
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.